Companies › Veloxis Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VEL-101 CD40-CD154 pathway antagonist (costimulation blockade) | CD40 | Phase 2 | Transplantation, Kidney | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07290777 | VEL-101 | Phase 2 | Transplantation, Kidney | Genitourinary | Oct 2028 |
AbbVie Xencor Genmab RANI Therapeutics Roche Akamis Bio Alligator Bioscience Novartis
Kira Pharmacenticals (US) Juro Sciences Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma Tioga Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.